Education
About Us
Working with TipRanks
Follow Us
Universe Pharmaceuticals (UPC)
NASDAQ:UPC
RESEARCH TOOLSreports
Top Page
Universe Pharmaceuticals
(NASDAQ:UPC)
Rating:51Neutral
Price Target:―
Universe Pharmaceuticals (UPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.54M
Dividend YieldN/A
Average Volume (3M)632.04K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees225
SectorHealthcare
Sector Strength43
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-5.10
Shares Outstanding563,338
10 Day Avg. Volume330,508
30 Day Avg. Volume632,041
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Universe Pharmaceuticals Business Overview & Revenue Model
Company DescriptionUniverse Pharmaceuticals (UPC) is a pharmaceutical company that focuses on developing, manufacturing, and marketing traditional Chinese medicine (TCM) products. The company operates in the pharmaceutical sector, providing a range of herbal medicines and other health products primarily targeting elderly patients who suffer from chronic health conditions. Its core products include medicinal liquor, ointments, and capsules formulated using traditional Chinese medicinal practices.
How the Company Makes MoneyUniverse Pharmaceuticals makes money through the sale of its traditional Chinese medicine products, which are distributed across various retail and wholesale channels. Its revenue model is primarily based on the production and sale of these TCM products to pharmacies, hospitals, and healthcare facilities. The company also collaborates with research institutions to develop new formulations and improve existing products. Additionally, Universe Pharmaceuticals may engage in partnerships with other pharmaceutical companies to expand its product offerings and market reach, contributing to its earnings.
Universe Pharmaceuticals Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 26.73M | 32.31M | 40.14M | 47.98M | 30.70M | 33.23M | Gross Profit |
| 7.31M | 10.32M | 21.89M | 25.33M | 14.09M | 13.41M | EBIT |
| -5.42M | -3.53M | -7.02M | 13.59M | 10.25M | 9.75M | EBITDA |
| -15.86M | -3.22M | -7.33M | 14.20M | 10.61M | 10.17M | Net Income Common Stockholders |
| -18.55M | -6.16M | -8.74M | 11.32M | 7.56M | 7.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 11.80M | 18.50M | 18.86M | 21.80M | 10.06M | 3.18M | Total Assets |
| 26.78M | 53.29M | 59.54M | 70.14M | 28.80M | 17.84M | Total Debt |
| 2.54M | 5.48M | 3.94M | 4.33M | 2.65M | 2.52M | Net Debt |
| -9.26M | 197.21K | -1.78M | -3.74M | -7.41M | -655.52K | Total Liabilities |
| 9.30M | 13.75M | 13.10M | 11.21M | 8.00M | 5.45M | Stockholders Equity |
| 17.48M | 39.53M | 46.44M | 58.93M | 20.80M | 12.38M |
| Cash Flow | Free Cash Flow | ||||
| -6.18M | 1.08M | -1.41M | -15.59M | 6.06M | 13.12M | Operating Cash Flow |
| -6.07M | 1.12M | -1.31M | -2.06M | 6.12M | 13.20M | Investing Cash Flow |
| -111.18K | -44.17K | -3.91M | -27.06M | -51.80K | -86.03K | Financing Cash Flow |
| 2.60M | -1.39M | 3.32M | 26.58M | 470.14K | -16.00M |
Universe Pharmaceuticals Technical Analysis
Neutral
6.03
Price Trends
4.30
Positive
9.42
Negative
341.77
Negative
Market Momentum
0.33
Negative
60.25
Neutral
51.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPC, the sentiment is Neutral. The current price of 6.03 is above the 20-day moving average (MA) of 4.88, above the 50-day MA of 4.30, and below the 200-day MA of 341.77, indicating a neutral trend. The MACD of 0.33 indicates Negative momentum. The RSI at 60.25 is Neutral, neither overbought nor oversold. The STOCH value of 51.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UPC.
Universe Pharmaceuticals Risk Analysis
Universe Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Universe Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Universe Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
UPC
Universe Pharmaceuticals
5.58
-1,488.42
-99.63%
CPHI
China Pharma Holdings
2.24
-0.92
-29.11%
YCBD
cbdMD
0.94
-4.73
-83.42%
COSM
Cosmos Holdings
0.45
-0.25
-35.71%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.